Literature DB >> 18804773

Determination of arylamines and aminopyridines in pharmaceutical products using in-situ derivatization and liquid chromatography-mass spectrometry.

Gerd Vanhoenacker1, Emmie Dumont, Frank David, Andrew Baker, Pat Sandra.   

Abstract

Arylamines and aminopyridines form a class of potentially genotoxic impurities (PGIs) that can be present at trace levels in active pharmaceutical ingredients (APIs). A generic method was developed that allows the analysis of a selected set of these solutes at sub-ppm level relative to the drug substance. A highly concentrated solution of the pharmaceutical compound is analyzed by LC-MS using a single quadrupole mass spectrometer in the selected ion monitoring (SIM) mode. Since a number of target compounds show little or no retention in the reversed-phase LC setup, a fast and simple derivatization procedure using hexylchloroformate was applied. The amide derivatives of the PGI result in a higher molecular weight (more specific ion for SIM) and better chromatographic behavior. The methodology, consisting of a dual run on respectively a non-derivatized and a derivatized sample, was validated and applied to a selection of pharmaceutical substances. The method was found to be sufficiently sensitive and robust and is applicable in a QA/QC environment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18804773     DOI: 10.1016/j.chroma.2008.08.102

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  2 in total

1.  Spectrofluorimetric determination of selected genotoxic impurities in pharmaceutical raw materials and final products.

Authors:  Aliaa I Shallan; Ali Abdel-Hakim; Mohamed A Hammad; Maha M Abou El-Alamin
Journal:  Sci Rep       Date:  2022-09-12       Impact factor: 4.996

2.  Enrichment and characterization of a bacterial culture that can degrade 4-aminopyridine.

Authors:  Shinji Takenaka; Ryosuke Nomura; Ayumi Minegishi; Ken-ichi Yoshida
Journal:  BMC Microbiol       Date:  2013-03-21       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.